Rituximab-containing salvage chemotherapy followed by high-dose therapy and autologous stem cell transplant (ASCT) in chemosensitive patients remains the standard of care for patients with relapsed and refractory diffuse large B-cell lymphoma (DLBCL). However, its role in those patients achieving less than a complete response to first-line therapy (primary refractory disease) in the rituximab era is not well defined. We reviewed the outcomes of 82 transplant-eligible patients with primary refractory DLBCL who underwent salvage therapy with the intent of administering high-dose therapy and ASCT to patients achieving chemosensitive remission. The estimated 3-year overall and progression-free survival for all patients was 38% and 29%, respectively, and 65% and 60% respectively for patients proceeding to stem cell transplant. Long-term remission was achieved in 45% of patients achieving a partial response (PR) to initial induction therapy and <20% of patients with stable or progression of disease following initial therapy. These results suggest that salvage chemotherapy with the intent of subsequent high-dose therapy and ASCT remains a feasible strategy in certain patients with primary refractory DLBCL, particularly for those achieving a PR to frontline therapy. The primary barrier to curative therapy in patients with primary refractory disease is resistance to salvage therapy, and future studies should be aimed towards increasing the response rate in this population.
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Approximately 10-15% of patients with diffuse large B-cell lymphoma DLBCL treated with R-CHOP [rituximab, cyclophosphamide, hydroxydaunomycin (doxorubicin) , Oncovin (vincristine) , prednisone] fail to achieve a complete response (CR) and have documented persistent disease at the completion of first-line therapy (Coiffier et al, 2002; Feugier et al, 2005) . This has been referred to as primary refractory disease (Philip et al, 1987; Gribben et al, 1989; Vose et al, 1993 Vose et al, , 2001 Kewalramani et al, 2000; Hamlin et al, 2003) although it has also been defined as patients achieving less than a PR to front-line therapy (Mills et al, 1995; Villela et al, 2001) , patients achieving less than a PR to front-line therapy, or patients progressing within 3 months of completion of treatment (Telio et al, 2012; Hitz et al, 2015) . The standard treatment for patients with DLBCL in first relapse is rituximab combined with salvage chemotherapy (ST). For those achieving either a PR or CR to ST, consolidation with highÀdose therapy and autologous stem cell transplant (HDT/ ASCT) is the standard of care (Philip et al, 1995) . Data from two randomized studies and one registry study in the rituximab era suggest that 40-50% of patients are ultimately cured with this strategy (Vose et al, 2001; Gisselbrecht et al, 2010; Crump et al, 2014) ; however, a minority of patients in these studies had primary refractory disease. Earlier data demonstrated few long-term survivors amongst patients with primary refractory disease to CHOP (Philip et al, 1987; Villela et al, 2001; Martin et al, 2008; Hitz et al, 2015) with the benefit of HDT/ASCT restricted to the few patients who achieved a chemosensitive response to salvage chemotherapy (Stiff et al, 1998; Vose et al, 2001) . A retrospective analysis of 85 transplant-eligible patients with primary refractory disease following CHOP chemotherapy who were treated at the Memorial Sloan Kettering Cancer Center (MSKCC) with ICE (ifosfamide, carboplatin, etoposide) chemotherapy demonstrated a 3-year event-free and overall survival of 25% and 22%, respectively (Kewalramani et al, 2000) . The outcomes of transplanteligible patients with primary refractory DLBCL in the rituximab era remain unknown. Furthermore, whether the outcomes of all patients who fail to achieve a CR to first-line therapy for DLBCL have equivalent outcomes with salvage therapy or whether outcomes vary depending on chemosensitivity to frontline therapy, has not been established.
We reviewed patients with a diagnosis of DLBCL between 2002 and 2014 and identified 82 patients with primary refractory disease, described as failure to achieve CR to front-line, rituximab-and anthracycline-containing regimens, and who were subsequently treated with ST with intent to consolidate with HDT/ASCT. We assessed outcomes for these patients, including progression-free (PFS), event-free (EFS) and overall survival (OS), and evaluated the effect of key clinicopathological characteristics, including the secondline International Prognostic Index (IPI) score, nature of response to primary therapy (primary partial responders or primary progressors), response to salvage therapy, and histological classification of DLBCL, on outcomes.
Materials and methods

Patients
Transplant-eligible patients with DLBCL that achieved less than a CR to initial rituximab and anthracycline-containing regimens between 2002 and 2014 were identified. Patients with histological diagnoses of DLBCL, grey zone lymphoma, B-cell lymphoma unclassifiable, and transformed low-grade lymphoma were included. We excluded patients with primary mediastinal large B-cell lymphoma, as these patients are known to have distinct disease biology and superior outcomes as compared with DLBCL-not otherwise specified (NOS) (Rosenwald et al, 2003; Dunleavy et al, 2013) . Transplant eligibility was determined by the treating oncologist. Patients not treated with standard salvage platinum and anti-CD20 containing regimens and patients deemed ineligible for HDT/ASCT at the initiation of ST were excluded. Primary refractory disease was defined as a failure to achieve a CR with a front-line regimen containing rituximab and an anthracycline. Determination of refractory disease was based on radiographic (17%) or biopsy proven (83%) progression at the end of therapy; patients who had persistent disease documented by imaging rather than biopsy, had both clear radiographic progression of disease [defined as an increase in the size of old sites or new sites of disease by computed tomography (CT) or maximum standardized uptake value (SUV max ) > 10 on positron emission tomography (PET)] and also had sites of disease involvement inaccessible outside of an open surgical procedure. Patients with primary refractory disease were further sub-classified as either primary partial responders (PR to initial therapy) or primary progressors (minimal or no response to initial therapy); 86% of primary partial responders and 81% of primary progressors underwent biopsy to document refractory disease. Approval for this retrospective review was obtained from the Institutional Review and Privacy Board at MSKCC.
Eligibility for salvage therapy
All patients were staged according to standard Ann Arbor criteria (Lister et al, 1989) . All patients had adequate cardiac function (left ventricular ejection fraction >50%) and renal function (serum creatinine ≤132Á6 lmol/l or creatinine clearance ≥60 ml/min or higher) to undergo platinum-based chemotherapy.
Salvage chemotherapy and response criteria
ST was administered as previously described (Kewalramani et al, 2004; el Gnaoui et al, 2007; Gisselbrecht et al, 2010; Matasar et al, 2013; Crump et al, 2014) . PET-CT was performed within 4 weeks of initiation of ST and either PET-CT or CT of the chest, abdomen, and pelvis was performed within 4 weeks of completion of the third cycle of ST. Response criteria were per the International Harmonization Project (IHP) when pre-and post-ST PET were available, otherwise by the sum of the product of the diameters (SPD) on CT scan as per the International Working Group (Cheson et al, 1999 (Cheson et al, , 2007 and were compared to the reference imaging study performed following completion of first-line therapy.
High-dose therapy and autologous stem cell transplantation
Patients deemed to have chemosensitive disease by their treating oncologist were eligible for HDT/ASCT. Granulocyte colony-stimulating factor mobilized peripheral blood progenitor cells (PBPC) were typically collected on recovery from the third cycle of ST; a minority of patients required second mobilization attempts or the addition of plerixafor to augment stem cell yield. All patients undergoing HDT/ASCT were required to have adequate pulmonary function (diffusion capacity greater than 50% of predicted) and liver function (serum bilirubin level < 34Á2 lmol/l). The choice of the conditioning regimen depended on the patient's age, the extent of prior therapy, and the clinical trials active at the time of transplantation. Pre-transplant involved field radiotherapy (IFRT) was administered at the discretion of the primary physician, typically in the setting of refractory disease that was confined to a single radiation port.
Statistical analysis
The endpoints of interest, PFS, EFS and OS, were assessed from the first day of ST in the intention-to-treat cohort and day of transplant for the transplanted subset analysis. PFS was defined from the starting point until progression or death, and patients who were alive and progression-free at the end of the study period were censored at the date of last available follow-up. EFS was defined from the starting point until treatment failure, relapse, death from all causes, toxicity due to ST or HDT/ASCT, or secondary malignancy, whichever came first, and patients who did not experience any of these events were censored at the date of last follow-up. OS was defined from the starting point until death, and patients who did not die during the study period were censored at the date of last follow-up. All three endpoints were analysed using the Kaplan-Meier method and Cox proportional hazards models (Cox, 1972) .
Factors known at the time of initiation of ST that were selected as possible prognostic indicators of PFS or OS included: age (younger than 60 years vs. 60 years or older), gender, histological classification (DLBCL-NOS vs. transformed vs. other), cell-of-origin [germinal centre B-cell (GCB) vs. non-GCB by Hans criteria (Hans et al, 2004) ], primary treatment response (partial responders vs. primary progressors), Ann Arbor stage (I/II vs. III/IV), disease bulk (less than 5 cm vs. 5-10 cm. vs. more than 10 cm in longest axis), lactate dehydrogenase (LDH; normal vs. elevated), Karnofsky Performance Status (KPS; less than 80 vs. 80 or greater), number of extranodal sites of disease (1 or (Lerner et al, 2007) . Factors that were significant in univariate analysis (P < 0Á05) were candidates for a multivariate model, which was created using a stepwise backward selection procedure (Mantel, 1966) . Analysis of PET response to salvage therapy by IHP as a prognostic indicator of PFS or OS was analysed separately on the cohort of patients who underwent PET restaging. The overall response rate (ORR) was calculated as a proportion, including an exact 95% confidence interval (CI), and was compared with primary treatment response using a chisquared test. All statistical tests were two-sided, and 5% was set as the level of significance. Statistical analyses were performed using R 3.2.0 (R Core Team 2015), including the 'survival' and 'Hmisc' packages.
Results
Patient characteristics
Pre-ST treatment characteristics of the 82 patients are shown in Tables I and II. Median age was 57 (range 25-73) years; 37% were older than 60 years and 61% were male. With respect to histology, 73% of patients had DLBCL-NOS, 13% had transformed low-grade B cell lymphoma, 7% had T-cell rich B-cell lymphoma, 4% had grey zone lymphoma and 2% had B-cell lymphoma unclassifiable. With respect to initial treatment response, 34% of patients were partial responders whereas 66% were primary progressors. An elevated LDH, KPS <80 and Ann Arbor stage III-IV disease were seen at relapse in 68%, 20% and 62% of patients, respectively. Bulky disease (>10 cm) and multiple (≥2) extranodal sites of disease were present in 17% and 43% of patients. An elevated second-line IPI (≥3) and aaIPI (≥3) were seen in 49% and 55% of patients, respectively.
Response to salvage chemotherapy 71% of patients received ICE and rituximab (R-ICE) and 26% received DHAP (dexamethasone, high-dose cytarabine, cisplatin) or DHAX (dexamethasone, high-dose cytarabine, oxaliplatin) chemotherapy in combination with rituximab or ofatumumab (Table II) . Sixty-three (77%) of the 82 patients completed the total planned number of cycles of ST. Of the 19 patients who did not complete all planned cycles, 16 had progression of disease during therapy, usually detected by interim restaging CT scan performed after two cycles of ST. Three patients did not complete three cycles due to toxicity; one patient developed ifosfamide neurotoxicity and was switched from R-ICE to R-EPOCH (rituximab, etoposide, prednisone, Oncovin, cyclophosphamide, hydroxydaunomycin). Two patients suffered fatal infectious complications during ST (cytomegalovirus pneumonitis and septic shock). The ORR to ST was 56% (95% CI 45-67%), with 18% achieving a CR and 38% achieving a PR. Primary partial responders had a non-statistically significant higher ORR and CR rate as compared to primary progressors (ORR 68 vs. 50%, P = 0Á19, CR 25 vs. 15%, P = 0Á41). There was no difference in response rates between patients who received ofatumumab and rituximab, as has been previously reported (Matasar et al, 2013; van Imhoff et al, 2014) . There was also no difference in response rates between histological subtypes.
PET scans were performed on 70 (85%) of patients. In patients in whom PET data was available, the ORR by PET was 70%, with 26% achieving a PET CR (defined as Deauville 1-3) and 44% achieving a PET PR (defined as Deauville 4). Primary partial responders had a non-statistically significant higher ORR and CR rate by PET as compared to primary progressors (ORR 80 vs. 64%, P = 0Á27, CR 35 vs. 20%, P = 0Á16).
HDT and ASCT
Thirty-seven (45%) patients proceeded to consolidative stem cell transplant; 33 of whom underwent ASCT and four patients underwent allogeneic stem cell transplant at the discretion of their providers. Of the patients undergoing ASCT, the overwhelming majority (88%) had chemosensitive disease with 27% achieving a CR and 61% achieving a PR. Four patients with stable disease proceeded to HDT/ASCT; all of these patients had improvement in disease burden but failed to meet the criteria for PR and all received radiotherapy to Primary Refractory DLBCL in the Rituximab Era ª 2016 John Wiley & Sons Ltd persistently involved sites sides prior to transplant. Thirteen patients who achieved a chemosensitive remission did not proceed to ASCT in first remission; 11 of these patients experienced rapid progression of disease between their restaging imaging study and admission for planned ASCT. One patient underwent allogeneic SCT following definitive IFRT to areas of chemorefractory disease, and in one patient ASCT was deferred due to poor functional status.
The characteristics and conditioning regimens for patients proceeding to HDT/ASCT are listed in Table III . The majority (97%) of patients received one of three conditioning regimens: BEAM (carmustine, etoposide, cytarabine, melphalan) (70%), CBV (cyclophosphamide, carmustine, etoposide) (8%), or IE (ifosfamide, etoposide, total body irradiation) (8%). Eighteen (55%) of the patients who underwent HDT/ ASCT received hyperfractionated IFRT prior to transplant. There was one (2Á7%) possible transplantation-related death, due to peri-transplant neutropenic sepsis with subsequent multi-organ failure. An additional three patients (total of 4, or 12%) of 33 patients died within 100 days of stem cell reinfusion, all due to diffuse progression of disease.
Overall and progression-free survival
Median follow-up for survivors was 33 months. The estimated 3-year OS and PFS were 38% and 29% respectively (Fig 1) . Primary partial responders to initial therapy had a statistically superior OS and PFS as compared to primary progressors (P = 0Á006 for OS and 0Á008 for PFS) (Fig 2) ; 49% of primary partial responders were progression free at 3 years compared to 17% of primary progressors. The PFS of patients differed significantly by response to salvage therapy as determined by PET; patients with a Deauville 1-3 response had an estimated 3-year PFS of 68%, as compared to 30% in patients with a Deauville 4 response and 0% in patients with a Deauville 5 response (P < 0Á001) (Fig 3) . With respect to patients proceeding to ASCT, median follow-up for survivors from the date of SCT was 37 months.
The estimated 3-year OS and PFS of patients proceeding to transplant was 65% and 60% respectively (Fig 4) . There were insufficient events to perform a univariate or multivariate analysis of risk factors in the transplanted cohort. However, patients with early stage disease who received pre-ASCT IFRT had a superior PFS to those who did not receive IFRT (data not shown).
Nine of 45 patients who did not undergo consolidative transplant after first ST are alive and two remain free from disease progression at the time of last follow-up. Only two patients who did not proceed to HDT/ASCT following first ST remain alive after 2 years of follow-up. One patient achieved a chemosensitive remission to third-line R-EPOCH and IFRT following progression of disease to R-ICE therapy and subsequently underwent HDT/ASCT. The other patient failed to collect adequate stem cells for HDT/ASCT. He was treated with IFRT to the right adrenal gland and relapsed 7 months later in the central nervous system. 
All values are given as n (%) unless otherwise indicated. ASCT, autologous stem cell transplantation; BEAM, BCNU (carmustine), etoposide, cytarabine, melphalan; IFRT, involved field radiotherapy; CBV-M, cyclophosphamide, BCNU (carmustine), etoposide; CR, complete response; HDT/ASCT, high dose therapy/autologous stem cell transplant; IE, ifosfamide, etoposide; PR, partial response; SD, stable disease. 
Prognostic factors
Within the ITT cohort, univariate analysis revealed that age ≥60 years, primary progressive disease, bulk >10 cm (vs. <5 cm), elevated LDH, KPS <80, multiple extranodal sites of disease, and an elevated second-line IPI were associated with inferior PFS. With respect to histological subtype, there was no difference between GCB and non-GCB subtypes of DLBCL with respect to PFS. There was no association between PFS with gender, stage, or bone marrow involvement. Multivariate analysis revealed KPS <80 and an elevated LDH to be independently associated with PFS; patients with either or both of these risk factors had a hazard ratio of 3Á01 and 4Á52 for disease progression, respectively, as compared to patients with neither of these risk factors (Fig 5; Table IV ). The independent association of primary progressive disease with PFS approached statistical significance in a multivariate analysis (hazard ratio 1Á82 versus partial responders, P = 0Á057).
Discussion
Optimal management of patients with primary refractory DLBCL has remained uncharacterized for a variety of reasons. There are no randomized trials restricted to patients with primary refractory DLBCL; all prospective studies have included patients with both relapsed and refractory disease. The definition of primary refractory disease has been variable, with most retrospective analyses including both patients with true refractory disease and patients with early relapse. Finally, the efficacy of HDT/ASCT in patients with primary refractory disease remains unclear. Prior studies, including results from the Autologous Blood and Marrow Transplant Registry (ABMTR) and the Southwest Oncology Group (SWOG) have suggested that HDT/ASCT may be beneficial in patients with chemosensitive disease (Stiff et al, 1998; Vose et al, 2001) , but the patients in these studies did not receive rituximab as part of front-line therapy. In our cohort of patients with primary refractory DLBCL, primary refractory was strictly defined as patients failing to achieve CR to first-line anthracycline-based chemoimmunotherapy and having either primary partial response or primary progression. The ORR to salvage regimens of was 56% with a CR rate of 18%. This is comparable to published subgroup analyses of response rates in patients with refractory disease or early relapse; for example, in the Collaborative Trial in Relapsed Aggressive Lymphoma (CORAL) study, the overall response rate in patients with refractory or early relapsed (<12 months) disease was 46% (Gisselbrecht et al, 2010) .
Approximately 38% of our patients with primary refractory disease are alive, and 29% are progression-free 3 years from initiation of ST. Our outcomes are somewhat favourable compared to existing data regarding patients with primary refractory DLBCL in the rituximab era. However, our cohort includes only patients treated with standard ST and intent to proceed to autologous transplant in chemosensitive patients, whereas most studies showing a comparatively poor outcome in primary refractory disease included patients treated with palliative intent (Villela et al, 2001; Vose et al, 2001; Telio et al, 2012; Rovira et al, 2015) .
Our data demonstrate that outcomes of certain patients who are able to tolerate salvage therapy are similar to patients with relapsed disease. In particular, patients with a PR or better to front-line therapy had outcomes similar to historical relapsed patients, with about 45% achieving long-term remissions. Conversely, patients with primary progressive disease were cured in less than 20% of cases; this result is similar to outcomes of patients in the CORAL study with relapsed disease less than 12 months following rituximab-containing initial regimens (Gisselbrecht et al, 2010) . Our data from patients undergoing restaging PET-CT after salvage chemotherapy suggests that patients who achieve a PET CR to first salvage are cured in nearly 70% of cases whereas only 30% of PET-avid chemosensitive patients achieve long-term remissions. These results are similar to data in the relapsed setting in which nearly 80% of PET-negative and 50% of PET-avid chemosensitive patients were cured with a similar strategy (Sauter et al, 2015) .
Our data further suggest that HDT/ASCT is a safe and effective consolidation strategy in this population. Patients with chemosensitive disease who proceeded to HDT/ASCT had a 3-year OS of 65% and PFS of 60%, with only one transplant-related death. Our results are consistent with a recent report suggesting that early failure of frontline rituximab-based chemoimmunotherapy did not predict futility of ASCT, with a 3-year OS of 59% (Hamadani et al, 2014) . Our rate of long-term disease control without significant transplant-related morbidity compares favourably with reduced-intensity conditioning allogeneic transplant, which, in a similar setting, resulted in a 3-year OS of 38% but was accompanied by grade 2 or higher GVHD in more than 40% of cases (Glass et al, 2014) . Of note, the outcomes of patients who did not achieve a remission-adequate response to first ST and proceed to transplant were uniformly poor. These results are consistent with the overall poor outcomes of patients who do not respond to second-ST, with median OS of well less than 1 year (Elstrom et al, 2010) and few longterm survivors (Ardeshna et al, 2005) , and differs from patients with relapsed disease, many of whom can be cured with third-line salvage chemotherapy and ASCT (van den Neste et al, 2016) . Our data strongly suggest that patients with primary refractory disease who do not enjoy an adequate response to first ST are unlikely to achieve a chemosensitive remission with conventional strategies and underscores the need for novel therapies aimed at improving the response rate to first ST in this population. However, our data also demonstrates that patients with a PR or better to front-line therapy have outcome similar to those with relapsed disease and should not be excluded from any clinical trials enrolling relapsed patients.
A number of univariate factors were prognostically significant in our cohort. Patients with a PR to induction therapy, as well as younger patients and patients with a low secondary IPI, demonstrated favourable outcomes, whereas elderly patients and patients with an elevated second-line IPI had comparatively poor outcomes. This is similar to patients with relapsed DLBCL, in whom the second-line age-adjusted IPI is associated with long-term outcomes, largely through its association with response to ST (Hamlin et al, 2003) . Elderly patients with an elevated second-line IPI (and particularly those with an elevated LDH) derive limited benefit from conventional strategies and may benefit from novel therapeutic approaches. Notably, cell of origin was not found to be associated with outcomes, consistent with its lack of prognostic value in relapsed disease (Moskowitz et al, 2005; Costa et al, 2008) .
In summary, this is the largest reported series of patients with primary refractory DLBCL treated with curative intent in the rituximab era. ST with consolidative ASCT leads to a durable remission in about 45% of patients with a PR to front-line therapy, but in fewer than 20% of patients with primary progressive disease. Patients with chemosensitive disease proceeding to ASCT achieve long-term remission in 60% of cases. This data suggests that transplant-eligible patients with DLBCL and a PR or better to frontline therapy should be treated with standard salvage regimens and consolidation with HDT/ASCT in patients with chemosensitive disease, as their outcomes are similar to patients with relapsed disease. Patients with primary progressive DLBCL are less chemosensitive to conventional ST and we would recommend investigational strategies in this population to increase the likelihood of proceeding to transplant. Patients with an elevated LDH or poor performance status also respond poorly to conventional ST and investigational approaches may also be more appropriate in this setting. 
